[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
TS-1, a novel oral formation of 5-fluorouracil that consists of 1 M tegafur (FT), 0.4 M gimeracil and 1 M otacil potassium, was reported to achieve a relatively high response rate of 49% in patients with advanced gastric cancer in a late phase II study. We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy. A 79-year-old man, who had nothing of note in his past or family history, presented with multiple liver tumors and type 3 gastric tumor. His diagnosis was inoperable gastric cancer with liver metastases, and he underwent outpatient treatment of oral administration of TS-1, following FMP therapy under hospitalization. The main and metastatic lesions shrunk dramatically with the two courses of the chemotherapy. There were no noticeable adverse effects. QOL has been maintained and the patient remains in good condition. TS-1 can be considered well-tolerable and quite effective for inoperable gastric cancer, especially if preceding therapy with 5-FU shows significant efficacy. TS-1 may therefore be a new candidate as a first line drug in outpatient cancer treatment.